FDA Declares Zepbound Shortage Over: What’s Next for Patients and Pharmacies?

The Food and Drug Administration (FDA) has announced that the shortage of Eli Lilly’s weight loss drug Zepbound is over, impacting the availability of cheaper compounded versions. This decision, based on comprehensive data analysis, suggests that Eli Lilly’s manufacturing efforts are now meeting or exceeding demand. However, this could leave patients like Willow Baillies, who rely on compounded tirzepatide due to its lower cost, in a difficult position. Baillies, who has lost 52 pounds and alleviated autoimmune issues with the compounded drug, now faces potential inaccessibility to this treatment. Compounded tirzepatide, costing around $350 per month, has been a lifeline for many without insurance coverage for Zepbound, which costs about $1,000 monthly. The FDA’s decision will largely prevent compounding pharmacies from producing these cheaper alternatives in the next two to three months, with specific deadlines set for different types of pharmacies. Despite the FDA’s declaration, some patients and experts question whether the shortage is truly resolved, as reports of supply issues persist. Meanwhile, the legal battle between the FDA and the Outsourcing Facilities Association continues, adding uncertainty to the future availability of compounded tirzepatide.

Source: https://www.cnbc.com/2024/12/24/fda-zepbound-shortage-impact-compounding-pharmacies-patients.html